@techreport{oai:kindai.repo.nii.ac.jp:00019751,
 author = {川村, 純一郎 and 杉浦, 史哲 and 奥野, 清隆},
 month = {},
 note = {研究成果の概要（和文）：StageIII大腸癌根治術患者に対する経口抗がん剤(UFT/LV)併用ペプチドワクチン療法の臨床的有効性、安全性を検証する第2相臨床研究を行った。主要評価項目である無再発生存期間(RFS)は、HLA-A24陽性・陰性群で有意差を認めなかったが、細胞障害性T細胞(CTL)反応陽性群で有意に予後良好との結果を得た。ペプチドワクチン投与後のCTL反応は、治療効果を予測する良い指標になりうる　
研究成果の概要（英文）：We conducted a phase II clinical trial involving patients with stage III CRC. All enrolled patients whose human leukocyte antigen (HLA)-A status was double-blinded were administered the same regime of a peptide vaccine and UFT/LV chemotherapy. The primary objective of the study was the comparison of relapse-free survival (RFS) in patients with HLA-A*2402 versus those without HLA-A*2402. A total of 46 patients were enrolled in the study. Three-year RFS was not significantly different between HLA-A*2402 matched and unmatched groups. Three-year RFS was significantly better in patients with positive CTL responses in the HLA-A*2402 matched group compared with those without. In conclusion, vaccination-induced immune responses combined with UFT/LV are positively associated with survival benefit in patients with HLA-A* 2402-positive stage III CRC., 研究種目：基盤研究(C);  研究期間：2015～2017;   課題番号：15K10153;   研究分野：消化器外科;   科研費の分科・細目：, application/pdf},
 title = {ステージIII大腸癌の再発予防におけるペプチドワクチン療法の優勢性に関する研究},
 year = {2018},
 yomi = {カワムラ, ジュンイチロウ and スギウラ, フミアキ and オクノ, キヨタカ}
}